Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Initiation of Angiotensin Receptor-neprilysin Inhibitor (ARNi) and Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF): the INITIATE-HFrEF Randomized Open-label Trial

NCT05989503 is registered in ClinicalTrials.gov with Universidade do Porto as lead sponsor.

NCT NCT05989503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05989503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Initiation of Angiotensin Receptor-neprilysin Inhibitor (ARNi) and Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF): the INITIATE-HFrEF Randomized Open-label Trial
Lead sponsor
Universidade do Porto
Phase
Phase 4
Overall status
Completed
Start date
August 4, 2023
Completion date
July 31, 2025
Enrollment
62 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with reduced ejection fraction